share_log

Johnson & Johnson | 10-Q: Q2 2024 Earnings Report

SEC ·  Jul 25 15:04

Summary by Moomoo AI

Johnson & Johnson (J&J) has been actively involved in a series of patent infringement lawsuits to protect its pharmaceutical products. In a significant development, the District Court ruled in favor of J&J in May 2023, finding Mylan's generic product infringed on J&J's patent, which Mylan has since appealed. J&J has also initiated legal actions against other entities for infringement on patents related to medications such as SYMTUZA, ERLEADA, SPRAVATO, and INVOKANA. Additionally, J&J's MedTech segment has been engaged in litigation, notably with Abiomed, Inc. securing a favorable judgment regarding non-infringement of Maquet patents. J&J is also responding to government inquiries and investigations, including those related to the Foreign Corrupt Practices Act and...Show More
Johnson & Johnson (J&J) has been actively involved in a series of patent infringement lawsuits to protect its pharmaceutical products. In a significant development, the District Court ruled in favor of J&J in May 2023, finding Mylan's generic product infringed on J&J's patent, which Mylan has since appealed. J&J has also initiated legal actions against other entities for infringement on patents related to medications such as SYMTUZA, ERLEADA, SPRAVATO, and INVOKANA. Additionally, J&J's MedTech segment has been engaged in litigation, notably with Abiomed, Inc. securing a favorable judgment regarding non-infringement of Maquet patents. J&J is also responding to government inquiries and investigations, including those related to the Foreign Corrupt Practices Act and the False Claims Act. Notably, the U.S. Department of Justice is investigating J&J Vision under the False Claims Act. Furthermore, J&J is managing litigation related to alleged anti-competitive behavior in Brazil and a complaint under the U.S. Anti-Terrorism Act. In terms of business development, J&J has completed a prioritization of its R&D investments, resulting in the discontinuation of certain programs, and has initiated a restructuring program within its Orthopaedics franchise. The company's future plans include focusing on the most promising medicines and streamlining operations to enhance efficiency.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated